Search
Zai Lab Ltd
ZLABAdd to Watchlist
20.590USD
+0.260+1.28%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
2.33BMarket Cap
LossP/E TTM
More Details of Zai Lab Ltd Company
Zai Lab Ltd is a holding company primarily engaged in biopharmaceuticals. The Company is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The Company has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.
Zai Lab Ltd Info
Ticker SymbolZLAB
Company nameZai Lab Ltd
IPO dateSep 28, 2020
CEODu (Ying)
Number of employees1869
Security typeDepository Receipt
Fiscal year-endSep 28
AddressBuilding B, 899 Halei Road, Pudong
CitySHANGHAI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryChina
Postal code201203
Phone862161632588
Websitehttps://www.zailaboratory.com/
Ticker SymbolZLAB
IPO dateSep 28, 2020
CEODu (Ying)
Company Executives of Zai Lab Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
117.60K
+22.60%
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+10.86%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-8.50%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
19.15K
-4.46%
Dr. Ying (Samantha) Du, Ph.D.
Dr. Ying (Samantha) Du, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Ms. Leung (Nisa Bernice) Wing-Yu
Ms. Leung (Nisa Bernice) Wing-Yu
Independent Director
Independent Director
--
--
Mr. Peter Karl Wirth, J.D.
Mr. Peter Karl Wirth, J.D.
Independent Director
Independent Director
--
--
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Mr. Leon Oliver (Lonnie) Moulder, Jr.
Independent Director
Independent Director
--
--
Mr. Frazor Titus Edmondson, J.D.
Mr. Frazor Titus Edmondson, J.D.
Company Secretary, Chief Legal Officer
Company Secretary, Chief Legal Officer
--
--
Mr. Scott W. Morrison, CPA
Mr. Scott W. Morrison, CPA
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Joshua L. Smiley
Mr. Joshua L. Smiley
President, Chief Operating Officer
President, Chief Operating Officer
117.60K
+22.60%
Dr. John David Diekman, Ph.D.
Dr. John David Diekman, Ph.D.
Lead Independent Director
Lead Independent Director
99.77K
+10.86%
Mr. William David (Bill) Lis
Mr. William David (Bill) Lis
Independent Director
Independent Director
35.11K
-8.50%
Dr. Yajing Chen, Ph.D.
Dr. Yajing Chen, Ph.D.
Chief Financial Officer
Chief Financial Officer
19.15K
-4.46%
Dr. Ying (Samantha) Du, Ph.D.
Dr. Ying (Samantha) Du, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Ms. Leung (Nisa Bernice) Wing-Yu
Ms. Leung (Nisa Bernice) Wing-Yu
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
By BusinessUSD
Name
Revenue
Proportion
ZEJULA
189.04M
41.35%
VYVGART
94.20M
20.60%
NUZYRA
60.84M
13.31%
Optune
48.33M
10.57%
QINLOCK
35.61M
7.79%
Other
29.17M
6.38%
By RegionUSD
Name
Revenue
Proportion
China (Mainland)
460.16M
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
ZEJULA
189.04M
41.35%
VYVGART
94.20M
20.60%
NUZYRA
60.84M
13.31%
Optune
48.33M
10.57%
QINLOCK
35.61M
7.79%
Other
29.17M
6.38%
Shareholding Stats
Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RTW Investments L.P.
6.19%
RA Capital Management, LP
5.11%
Norges Bank Investment Management (NBIM)
3.42%
Frazier Life Sciences Management, L.P.
1.69%
ClearBridge Investments, LLC
1.61%
Other
81.97%
Shareholders
Shareholders
Proportion
RTW Investments L.P.
6.19%
RA Capital Management, LP
5.11%
Norges Bank Investment Management (NBIM)
3.42%
Frazier Life Sciences Management, L.P.
1.69%
ClearBridge Investments, LLC
1.61%
Other
81.97%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
11.71%
Investment Advisor
5.60%
Venture Capital
5.36%
Hedge Fund
4.22%
Sovereign Wealth Fund
3.42%
Individual Investor
1.91%
Private Equity
1.69%
Research Firm
1.50%
Pension Fund
0.05%
Other
64.54%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
280
37.42M
42.38%
--
2026Q1
352
37.82M
33.67%
-10.78M
2025Q4
370
44.73M
39.84%
-12.84M
2025Q3
372
46.61M
41.70%
-15.37M
2025Q2
394
60.58M
54.15%
-11.96M
2025Q1
453
59.51M
53.68%
-14.18M
2024Q4
446
60.80M
55.47%
-4.29M
2024Q3
439
51.45M
51.99%
-10.14M
2024Q2
454
47.04M
47.66%
-14.67M
2024Q1
465
46.22M
46.47%
-13.77M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RTW Investments L.P.
6.96M
6.14%
+4.67M
+203.71%
Dec 31, 2025
Norges Bank Investment Management (NBIM)
3.84M
3.39%
+3.84M
--
Dec 31, 2025
Frazier Life Sciences Management, L.P.
1.90M
1.68%
+275.00K
+16.90%
Dec 31, 2025
ClearBridge Investments, LLC
1.81M
1.59%
-1.71M
-48.63%
Dec 31, 2025
Citadel Advisors LLC
1.69M
1.49%
+700.80K
+71.00%
Dec 31, 2025
Fidelity Management & Research Company LLC
1.44M
1.27%
-2.84M
-66.32%
Dec 31, 2025
Baron Capital Management, Inc.
1.42M
1.25%
+46.76K
+3.41%
Dec 31, 2025
Adar1 Capital Management LLC
1.25M
1.1%
+377.74K
+43.48%
Dec 31, 2025
Du (Ying Samantha)
1.06M
0.94%
+145.74K
+15.88%
Mar 11, 2026
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Tema Oncology ETF
1.67%
ALPS Medical Breakthroughs ETF
1.19%
Virtus LifeSci Biotech Products ETF
0.97%
Invesco Golden Dragon China ETF
0.58%
National Security Emerging Markets Index ETF
0.39%
iShares Biotechnology ETF
0.18%
Capital Group New Geography Equity ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
ActivePassive International Equity ETF
0.03%
View more
Tema Oncology ETF
Proportion1.67%
ALPS Medical Breakthroughs ETF
Proportion1.19%
Virtus LifeSci Biotech Products ETF
Proportion0.97%
Invesco Golden Dragon China ETF
Proportion0.58%
National Security Emerging Markets Index ETF
Proportion0.39%
iShares Biotechnology ETF
Proportion0.18%
Capital Group New Geography Equity ETF
Proportion0.15%
ProShares Ultra Nasdaq Biotechnology
Proportion0.12%
Invesco Nasdaq Biotechnology ETF
Proportion0.12%
ActivePassive International Equity ETF
Proportion0.03%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
